Global Anti fungal Drugs Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

The global antifungal drugs market is anticipated to increase at a significant CAGR over the forecast period due to rise in global population, and unhygienic environment. Burgeoning prevalence of infectious diseases, hospital acquired infections (nosocomial infections) coupled with rising awareness about the myriad fungal infections, and rising awareness of over-the-counter (OTC) antifungal drugs are the key factors expected to fuel the growth of the antifungal drugs market. In addition, rise in the R&D expenditure, increased funding from private and public sector for dermal infections, higher prevalence of chronic conditions, including HIV and cancer, rising of immunocompromised population, and increase in awareness by organizing patient education program are boosted the growth of antifungal drugs market over forecast period. However, the alternative therapies for fungal infections, patent expiries of branded drugs and availability of counterfeit drugs, stringent government policies, and adverse drug reactions of antifungal drugs are the major restraints for the growth of antifungal drugs over forecasting period.

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-anti-fungal-drugs-market/#ulp-4H8Z4LpNMLEuOnnx

The antifungal drugs market is segmented on the basis of drug class, route of administration, therapeutic indication, and distribution channel

Based on the drug class, antifungal drugs market is segmented into the following:
Azoles
Polyenes
Echinocandins
Allylamines
Others
Based on the route of administration, antifungal drugs market is segmented into the following:
Oral
Parenteral
Topical

Based on therapeutic indications, antifungal drugs market is segmented into the following:
Aspergillosis
Candidiasis
Dermatophytosis
Others

Based on distribution channel, antifungal drugs market is segmented into the following:
Retail pharmacies
Hospital pharmacies
Drug stores
Online pharmacies

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-anti-fungal-drugs-market/#ulp-c654SbFYO64MsOhu

The global antifungal drugs market is in blooming stage, several local and international players are actively involved in the development of antifungal drugs. The collaboration of government organizations for the increase in the awareness about fungal infections is expected to unlock the potential of antifungal drugs market. For instance, In November 2013, the CDC entered into a collaborative agreement with the National Health Ministry to enhance the treatment rates of communicable diseases in emerging countries, such as Brazil and India. Major acquisitions and collaborations among companies to commercialize antifungal drugs, mergers, launching of new products, and product approvals from various drug regulatory bodies such as U.S. FDA and EMEA enable increase the global antifungal drugs market growth. For instance, in October 2009, Mylan inks licensing deal with Pfizer to start selling a U.S. generic version of Pfizer’s Vfend antifungal drug. The increase in the prevalence of fungal infections also boosts the antifungal drugs market growth. According to Centres for Disease Control and Prevention (CDC), around one million people get infected worldwide by cryptococcal meningitis, which is a brain infection caused by fungus Cryptococcus and it subsequently leads to 625,000 deaths.

Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-anti-fungal-drugs-market/#ulp-14mlyhjMGhVjZqa3

Geographically, antifungal drugs market has been segmented into following regions Viz. North America, Asia-Pacific, Europe, Middle East and Africa, and Latin America. North America holds the largest share in the antifungal drugs market followed by Europe and Asia-Pacific, owing to increasing patient awareness, R&D expenditure for development of new drugs, and increase in prevalence rate of fungal infections in U.S. (According to Centre for Disease Control and Prevention (CDC) approximately 46,000 new cases of candidiasis occur every year in U.S.) Europe holds a major market share in anti-fungal drugs market attributed to increase in the prevalence rate of fungal infections in Europe and the development of antifungal biopharmaceuticals. Asia Pacific accounts for a significant growth owing to burgeoning consumer base and development in the economies of China and India. Rising income per capita, increasing awareness about the personal hygiene, and increase in healthcare expenditure might fuel the antifungal drugs market in Asia-Pacific region.

Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-anti-fungal-drugs-market/

Some of the players in antifungal drugs market are Pfizer, Inc. (U.S.), Novartis AG (Switzerland), Sanofi (France), Merck & Co., Inc. (U.S.), Enzon Pharmaceuticals, Inc. (U.S.), Bayer AG (Germany), Astellas Pharma, Inc. (Japan), GlaxoSmithKline plc. (U.K.), Mylan N.V. (U.S.), Tecan Group (Switzerland), and AureoGen Biosciences Inc. (U.S.), to name a few.

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.


Email: sales@precisionbusinessinsights.com
Toll Free(US): +1-866-598-1553"

Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX

This release was published on openPR.